Malaria Vaccine Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Biomolecular interactions between Plasmodium and human host: A basis of targeted antimalarial therapy
Ann Pharm Fr. 2024 Mar 20:S0003-4509(24)00040-3. doi: 10.1016/j.pharma.2024.03.005. Online ahead of print.ABSTRACTMalaria is one of the serious health concerns worldwide as it remains a clinical challenge due to the complex life cycle of the malaria parasite and the morphological changes it undergoes during infection. The malaria parasite multiplies rapidly and spreads in the population by changing its alternative hosts. These various morphological stages of the parasite in the human host cause clinical symptoms (anemia, fever, and coma). These symptoms arise due to the preprogrammed biology of the parasite in response to ...
Source: Annales Pharmaceutiques Francaises - March 22, 2024 Category: Drugs & Pharmacology Authors: Anamika Jain Rajeev Sharma Laxmikant Gautam Priya Shrivastava Kamalinder K Singh S P Vyas Source Type: research

A new malaria vaccination tool based on replication-competent Plasmodium falciparum parasites
EMBO Mol Med. 2024 Mar 21. doi: 10.1038/s44321-024-00056-8. Online ahead of print.NO ABSTRACTPMID:38514792 | DOI:10.1038/s44321-024-00056-8 (Source: Molecular Medicine)
Source: Molecular Medicine - March 22, 2024 Category: Molecular Biology Authors: Diana Moita Miguel Prud êncio Source Type: research

Monitoring of Lipid Fluxes Between Host and Plastid-Bearing Apicomplexan Parasites
Methods Mol Biol. 2024;2776:197-204. doi: 10.1007/978-1-0716-3726-5_12.ABSTRACTApicomplexan parasites are unicellular eukaryotes responsible for major human diseases such as malaria and toxoplasmosis, which cause massive social and economic burden. Toxoplasmosis, caused by Toxoplasma gondii, is a global chronic infectious disease affecting ~1/3 of the world population and is a major threat for any immunocompromised patient. To date, there is no efficient vaccine against these parasites and existing treatments are threatened by rapid emergence of parasite resistance. Throughout their life cycle, Apicomplexa require large am...
Source: Mol Biol Cell - March 19, 2024 Category: Molecular Biology Authors: Sarah Charital Amandine Lourdel Nyamekye Quansah Cyrille Y Bott é Yoshiki Yamaryo-Bott é Source Type: research

Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults
CONCLUSIONS PfSPZ Vaccine was safe and well tolerated in HIV+ vaccinees, but not protective. Vaccine efficacy was 80% in HIV– vaccinees (P = 0.012), whose sera had significantly higher inhibition of PfSPZ invasion of hepatocytes and enrichment of multifunctional PfCSP antibodies. A more potent PfSPZ vaccine or regimen is needed to protect those living with HIV against Pf infection in Africa.TRIAL REGISTRATION ClinicalTrials.gov NCT03420053.FUNDING Equatorial Guinea Malaria Vaccine Initiative (EGMVI), made up of the Government of Equatorial Guinea Ministries of Mines and Hydrocarbons, and Health and Social Welfare, Marath...
Source: Journal of Clinical Investigation - March 16, 2024 Category: Biomedical Science Authors: Said Jongo, L.W. Preston Church, Florence Milando, Munira Qassim, Tobias Schindler, Mohammed Rashid, Anneth Tumbo, Gloria Nyaulingo, Bakari M. Bakari, Thabit Athuman Mbaga, Latipha Mohamed, Kamaka Kassimu, Beatus S. Simon, Maxmillian Mpina, Irfan Zaidi, P Source Type: research

Next-Generation Vaccines for Tropical Infectious Diseases
Tropical infectious diseases impact on the quality of life across a large proportion of the global population. To meet the objectives of the World Health Organisation (WHO) Neglected Tropical Diseases and Malaria 2021-2030 roadmaps [1], the building of widespread capacity for the successful control and elimination of tropical infectious diseases over the next decade remains crucial. Ongoing advancements in the development of novel, effective and targeted vaccines play an integral role in the success of infectious diseases management worldwide [1]. (Source: International Journal of Infectious Diseases)
Source: International Journal of Infectious Diseases - March 16, 2024 Category: Infectious Diseases Authors: Tammy Allen, Maria Eugenia Castellanos, Paul Giacomin, Nadira D Karunaweera, Andreas Kupz, Juan Carlos LoL, Dileep Sharma, Suchandan Sikder, Bemnet Tedla, Liza van Eijk, Danica Vojisavljevic, Guangzu Zhao, Saparna Pai Source Type: research

Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine
In conclusion, CpG may confer enhanced efficacy for the rPSOP25 vaccine, as evidenced by the ability of the elicited antisera to induce protective immune responses and improved transmission-blocking activity.PMID:38460299 | DOI:10.1016/j.intimp.2024.111817 (Source: International Immunopharmacology)
Source: International Immunopharmacology - March 9, 2024 Category: Allergy & Immunology Authors: Xinxin Yu Hui Min Shijie Yao Guixiang Yao Di Zhang Biying Zhang Muyan Chen Fei Liu Liwang Cui Li Zheng Yaming Cao Source Type: research

Advancing Malaria Vaccination in Africa: Cameroon's Pioneering Effort and the Path Forward
Environ Health Insights. 2024 Mar 6;18:11786302241236013. doi: 10.1177/11786302241236013. eCollection 2024.NO ABSTRACTPMID:38449588 | PMC:PMC10916456 | DOI:10.1177/11786302241236013 (Source: Environmental Health Insights)
Source: Environmental Health Insights - March 7, 2024 Category: Environmental Health Authors: Olalekan John Okesanya Jerico Bautista Ogaya Emery Manirambona Chioma Ogochukwu Anorue Don Eliseo Lucero-Prisno Source Type: research